Spotlight Reports2018-04-04T16:33:58+00:00

Report Spotlights

RealTime Dynamix™: Atopic Dermatitis US Q3 2018 Spotlight

While dermatologists continue to report high satisfaction with the first FDA approved biologic, there is still a large unmet need for new pharmacologic treatments for atopic dermatitis. Sanofi/Regeneron’s Dupixent continues to exceed expectations and current users remain extremely satisfied with the first biologic approved to treat moderate-to-severe atopic dermatitis.

August 15, 2018|